Axonics Past Earnings Performance

Past criteria checks 0/6

Axonics has been growing earnings at an average annual rate of 21.7%, while the Medical Equipment industry saw earnings growing at 11.5% annually. Revenues have been growing at an average rate of 44.7% per year.

Key information

21.7%

Earnings growth rate

34.0%

EPS growth rate

Medical Equipment Industry Growth	8.9%
Revenue growth rate	44.7%
Return on equity	-0.3%
Net Margin	-0.4%
Last Earnings Update	30 Jun 2024

Recent past performance updates

Recent updates

A Look At The Fair Value Of Axonics, Inc. (NASDAQ:AXNX)

Jul 14

Axonics, Inc.'s (NASDAQ:AXNX) Earnings Haven't Escaped The Attention Of Investors

Jun 20

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 21% Discount?

Mar 27

Here's Why We're Not At All Concerned With Axonics' (NASDAQ:AXNX) Cash Burn Situation

Feb 28

Axonics: A Strong Medical Device Play With Significant Revenue Growth Opportunities

May 30

Axonics (NASDAQ:AXNX) Is In A Strong Position To Grow Its Business

Apr 19

We're Hopeful That Axonics (NASDAQ:AXNX) Will Use Its Cash Wisely

Sep 15

Revenue & Expenses Breakdown

How Axonics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:AXNX Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Jun 24	409	-2	265	42
31 Mar 24	387	-16	252	38
31 Dec 23	366	-6	235	35
30 Sep 23	343	-12	223	33
30 Jun 23	320	-32	213	33
31 Mar 23	296	-46	208	31
31 Dec 22	274	-60	196	34
30 Sep 22	241	-76	181	36
30 Jun 22	217	-77	168	37
31 Mar 22	194	-80	151	39
31 Dec 21	180	-80	136	37
30 Sep 21	162	-76	121	35
30 Jun 21	150	-68	109	34
31 Mar 21	120	-63	95	32
31 Dec 20	112	-55	92	29
30 Sep 20	87	-66	89	27
30 Jun 20	53	-82	87	24
31 Mar 20	39	-81	82	23
31 Dec 19	14	-80	68	20
30 Sep 19	4	-67	51	19
30 Jun 19	3	-49	34	18
31 Mar 19	2	-39	21	19
31 Dec 18	1	-32	13	19
30 Sep 18	0	-28	10	18
30 Jun 18	0	-25	7	17
31 Mar 18	0	-20	6	14
31 Dec 17	0	-18	6	12

Quality Earnings: AXNX is currently unprofitable.

Growing Profit Margin: AXNX is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: AXNX is unprofitable, but has reduced losses over the past 5 years at a rate of 21.7% per year.

Accelerating Growth: Unable to compare AXNX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AXNX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (7.5%).

Return on Equity

High ROE: AXNX has a negative Return on Equity (-0.27%), as it is currently unprofitable.

Axonics Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: EPS exceeds analyst expectations

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Axonics, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Axonics, Inc. Prevails in Patent Infringement Lawsuit with Medtronic

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

CEO & Director exercised options to buy US$7.1m worth of stock.

Forecast breakeven date moved forward to 2024

Axonics, Inc. Receives Regulatory Approval for Recharge-Free SNM System in Australia

Forecast breakeven date pushed back to 2025

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Shareholder dilution

Medtronic Files Itc Action Against Axonics to Stop Unauthorized Use of Medtronic Innovations

Full year 2023 earnings: EPS exceeds analyst expectations

Chief Commercial Officer exercised options and sold US$1.1m worth of stock

Insufficient new directors

BBoston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders for $3.6 billion.

BBoston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders for $3.6 billion.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) for $3.7 billion.

Chief Medical Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Axonics, Inc. Updates Revenue Guidance for the Fiscal Year 2023

Axonics, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Axonics, Inc. Announces Chief Financial Officer Changes

Chief Commercial Officer notifies of intention to sell stock

Forecast breakeven date moved forward to 2024

Axonics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

A Look At The Fair Value Of Axonics, Inc. (NASDAQ:AXNX)

Axonics, Inc.'s (NASDAQ:AXNX) Earnings Haven't Escaped The Attention Of Investors

Consensus estimates of losses per share improve by 37%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

President & CFO notifies of intention to sell stock

Now 20% undervalued after recent price drop

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 21% Discount?

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Full year 2022 earnings: EPS exceeds analyst expectations

Here's Why We're Not At All Concerned With Axonics' (NASDAQ:AXNX) Cash Burn Situation

Chief Operating Officer notifies of intention to sell stock

Now 21% undervalued after recent price drop

Executive VP exercised options and sold US$705k worth of stock

Axonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Chief Commercial Officer exercised options and sold US$1.9m worth of stock

Axonics, Inc. Provides Revenue Guidance for 2023

Forecast to breakeven in 2025

Axonics, Inc. to Report Fiscal Year 2022 Results on Jan 11, 2023

Independent Director recently sold US$135k worth of stock

Axonics, Inc. Receives Health Canada Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 32% Discount?

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Axonics, Inc. Updates Revenue Guidance for the Year 2022

Axonics, Inc. to Report Q3, 2022 Results on Oct 31, 2022

Axonics stock falls 5.6% after Needham downgrades rating

Chief Technology Officer notifies of intention to sell stock

Executive VP exercised options and sold US$551k worth of stock

Chief Medical Officer recently sold US$748k worth of stock

Axonics Announces First Patient Implants in Canada with New Recharge-Free Sacral Neuromodulation System

Axonics Stock Is A Buy Amid Current Capex Cycle

Executive VP notifies of intention to sell stock

Chief Operating Officer notifies of intention to sell stock

Consensus estimates of losses per share improve by 13%

Axonics prices stock offering of 1.75M shares

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Companies Like Axonics (NASDAQ:AXNX) Can Afford To Invest In Growth

Axonics, Inc. Updates Revenue Guidance for the Year of 2022

Axonics, Inc. to Report Q2, 2022 Results on Aug 01, 2022

Independent Director notifies of intention to sell stock

Axonics, Inc. Files PMA Supplement with FDA for Fourth Generation Rechargeable Neurostimulator

Axonics: A Strong Medical Device Play With Significant Revenue Growth Opportunities

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Axonics, Inc. Updates Revenue Guidance for the Fiscal Year 2022

Axonics, Inc. Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation System